PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's environmental, social, and governance practices.
72.38
ESG score exceeding 1.2x Biotechnology median of 59.90. Joel Greenblatt would verify if this ESG leadership translates to competitive advantages and pricing power.
62.46
Environmental score 1.1-1.2x Biotechnology median of 57.58. Philip Fisher would examine if superior environmental practices support long-term competitive positioning.
84.05
Social score exceeding 1.2x Biotechnology median of 63.84. Joel Greenblatt would verify if this social leadership translates to employee productivity and customer loyalty advantages.
70.64
Governance score 1.1-1.2x Biotechnology median of 61.84. Philip Fisher would examine if superior governance practices support long-term value creation.